Email:shdiahds@163.com
Phone:+1-909-839-7620
Fax:+1-909-839-7620
Click here for qusetions for this product!
Product Catalog
PEA-15 (D110) pAb
Current Country :
Download PDF Datasheet
Catalogue No : BS1573
| Host | Reactivity | Size | Application | stock | price | cart |
| Rabbit | H,M,R | 100μg | WB IHC IF |  |
258.00 |  |
|
Contact information
|
||||||
Product
1 mg/ml in Phosphate buffered saline (PBS) with 0.05% sodium azide, approx. pH 7.2.
Molecular Weight
~ 36 kDa
Purification & Purity
The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE).
Specificity
PEA-15 (D110) pAb detects endogenous levels of PEA-15 protein.
Applications (Recommended Dilutions)
WB: 1:500~1:1000 IHC: 1:50~1:200 IF: 1:50~1:200
Western Blot(WB)
Western blot (WB) analysis of PEA-15 (D110) pAb in extracts from Jurkat cells treated with PMA 125ng/ml 30'.
Immunohistochemistry (IHC)
Immunohistochemistry (IHC) analyzes of PEA-15 (D110) pAb in paraffin-embedded human colon carcinoma tissue.
Storage&Stability
Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.
Background
PEA-15 (phosphoprotein enriched in astrocytes) exists in an non-phosphorylated form (N), and two phosphorylated forms, Pa and Pb. PEA-15 is an endogenous substrate for PKC, which mediates the transition from Pa to Pb. The level of PEA-15 phosphorylation changes upon depolymerization or stabilization of tubulins, indicating that PEA-15 co-localizes with microtubules. The first 80 amino acids of PEA-15 correspond to the death effector domain (DED), which is a domain found in proteins that regulate apoptotic signaling pathways. The DED domain is necessary for PEA-15 to block Ras suppression. Although PEA-15 is predominantly expressed in the central nervous system, low levels of PEA-15 are expressed in liver and kidney, and higher levels in muscle.PEA-15 is also referred to as PED, phosphoprotein enriched in diabetes, for its elevated expression in type 2 diabetic patients